ANAB Company Profile and Key Details

Q: Who are the executives of ANAB?

Ms. Beth MuellerSenior Vice President of HRDr. Martin Dahl Ph.D.Senior Vice President of ResearchMr. Eric J. LoumeauChief Legal OfficerMr. Daniel R. FagaInterim Pres & Chief Executive Officer and DirectorMr. Hamza Suria M.B.A., M.Sc.AdvisoryDr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.Chief Medical OfficerMr. Dennis M. MulroyChief Financial OfficerMr. Benjamin StoneSenior Vice President of Corporation Devel.

NASDAQ : ANAB

AnaptysBio

$44.67

0.87+1.99%

At Close 4:00 PM

60.2

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

AnaptysBio, Inc. (ANAB) stock surged +1.99%, trading at $44.67 on NASDAQ, up from the previous close of $43.80. The stock opened at $43.95, fluctuating between $42.50 and $46.27 in the recent session.

Stock Snapshot

43.8

Prev. Close

1.24B

Market Cap

42.5

Day Low

-15.84

P/E Ratio

-2.82

EPS (TTM)

-4.57

Cash Flow per Share

43.95

Open

27.69M

Number of Shares

46.2678

Day High

91.42%

Free Float in %

3.31

Book Value

591.81K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 09, 2026	42.75	46.27	42.50	44.67	591.8K
Jan 08, 2026	44.25	45.02	43.49	43.80	1.75M
Jan 07, 2026	45.65	47.36	43.59	45.21	664.9K
Jan 06, 2026	42.46	44.18	42.00	43.91	465.47K
Jan 05, 2026	44.51	44.66	42.82	43.20	466.92K
Jan 02, 2026	48.28	48.57	44.80	44.95	438.39K
Dec 31, 2025	47.94	49.19	47.71	48.48	349.62K
Dec 30, 2025	50.69	51.00	46.89	48.23	543.07K
Dec 29, 2025	50.00	52.47	49.99	50.91	429.83K
Dec 26, 2025	50.00	50.18	49.50	50.10	197.91K
Dec 24, 2025	50.00	50.90	49.79	50.01	185.01K
Dec 23, 2025	50.00	51.27	49.14	50.04	406.94K
Dec 22, 2025	49.74	51.43	48.21	50.33	562.09K
Dec 19, 2025	47.61	49.90	47.54	49.08	740.84K
Dec 17, 2025	44.48	46.09	44.48	45.69	281.3K
Dec 16, 2025	45.10	46.00	44.03	45.03	318.08K
Dec 15, 2025	45.74	46.38	43.92	45.56	430.55K
Dec 12, 2025	45.80	46.82	44.45	44.94	309.27K
Dec 11, 2025	44.56	47.86	43.90	45.78	409.27K
Dec 10, 2025	43.71	45.39	43.60	44.95	318.14K

Contact Details

San Diego, CA 92121-5801

United States

https://www.anaptysbio.com 858 362 6295

About Company

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Stock Peers

REGN

-4.46-0.56%

Regeneron Pharmaceuticals, Inc.$796.55 ARGX

-7.07997-0.89%

argenx SE$788.49 MDGL

-42.16-7.58%

Madrigal Pharmaceuticals, Inc.$514.06 UTHR

-7.6-1.55%

United Therapeutics Corporation$483.23 VRTX

-5.82-1.24%

Vertex Pharmaceuticals Incorporated$463.86 ALNY

-1.11-0.28%

Alnylam Pharmaceuticals, Inc.$398.29 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-5.93-2.01%

Praxis Precision Medicines, Inc.$288.45 KRYS

12.5+5.02%

Krystal Biotech, Inc.$261.41 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

AnaptysBio, Inc. (NASDAQ:ANAB) closed at $44.67 USD, gaining $0.87 (1.99%) from the previous close of $43.80. The stock is currently mid-range between its 52-week high and low $12.21 and $52.47. With a market capitalization of about $1.24 billion, AnaptysBio, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.32). Key stats such as the average daily volume over the past year has been around 540.95 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, AnaptysBio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel R. Faga, the company employs approximately 136 people and listed since January 26, 2017. AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -4.7%, SMA50 6.4%, SMA200 59.49%). The stock’s 14-day RSI is 48.99 (neutral), while the ATR of 2.54 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.87% below its high and over 265.85% above its low. Average 10-day trading volume of 729.08 thousand shares is slightly above the 3-month average of 504.79 thousand, indicating heightened recent market interest.

Valuation Metrics

AnaptysBio, Inc. trades at a P/E ratio of -14.69, slightly below the S&P 500 average, with a price-to-sales ratio of 7.3 and a price-to-book ratio of -42.27 indicating negative book value, which may reflect financial stress. The P/FCF stands at -8.51, also below market averages.

Dividend & Fair Value

AnaptysBio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$13.94. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

AnaptysBio, Inc. generated EPS of -$2.82 over the past year. Five-year average earnings growth is -7.3%. Wall Street analysts project EPS growth of 4.12% annually over the next five years. The latest quarter delivered EPS of $0.52. The next quarter is forecast at $0.89. Next year's EPS is expected at -$7.86. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 7 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $100.00 to $19.00. The high target offers 123.86% upside. The low target suggests -57.47% downside. The mean target is $57.04. This offers 27.69% upside. AnaptysBio, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 04, 2025, missed forecasts by -149.06%. The prior quarter beat by -10.67%. Over the last six quarters, Apple has recorded several small beats. These include 42.5% in August 05, 2024.

Shareholding & Insider Activity

AnaptysBio, Inc. has 27.69 million shares outstanding. The public float is 14.42 million shares, elevated short interest at 38.69% of float. This equals 5.64 million shares. The short ratio is 10.19 days. Institutional investors hold 121.43% of the float. Insiders own 5.76%. EcoR1 Capital, LLC holds 7.88 million shares, NODELMAN OLEG has 7.52 million shares and Novo A/S has 3.03 million shares. Over the past six months, insider transactions show net selling. They sold 101.18 thousand shares across 18 transactions.

Financial & Profitability Overview

Over the trailing twelve months, AnaptysBio generated $17.16M in revenue, or $0.64 per share. Gross margin was 86.15%, operating margin -958.27%, and net profit margin -953.66%. Returns are negative, with ROA at -36.17% and ROE at -185.71%.
On valuation metrics, AnaptysBio trades at a P/E of -14.69, P/S of 7.30 and P/B of -42.27. The current ratio is 8.68 and quick ratio is 8.68. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1756.98 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -0.50, supported by a cash flow-to-debt ratio of -9.93.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, AnaptysBio posted revenue of $17.16M, down slightly from $10.29M in the prior quarter. Gross profit was $14.78M (margin 86.15%). Operating income was - $164.41M (margin -958.3%). Net income was- $163.62M (EPS - $6.08).
The company ended the quarter with $390.90M in cash and short-term investments, a total debt of $17.81M, and net debt of - $18.15M. Total assets were $452.39M, with equity of $88.10M. Financials further reflected weakness, with operating cash flow of - $120.80M, free cash flow of - $121.61M, and capital expenditures of - $807.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that AnaptysBio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.1%, with price expected at $38.82 by January 23, 2026, within a range of $37.01 to $40.52 3-Month Outlook: Projected rise of 85.02%, reaching $82.65 by April 09, 2026, with a range of $81.86 to $83.41. 1-Year Outlook: Projected gain of 12.11%, with price at $50.08 by December 31, 2026, within a range of $47.69 to $52.86.

Key Takeaways

AnaptysBio, Inc. (NASDAQ:ANAB) shares are flat -9.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows AnaptysBio, Inc. trading at a premium to the broader market with a P/E of -14.69. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $52.47, suggesting 17.46% upside. Our AI forecast model points to short-term weakness (-13.1% over two weeks), a medium-term rise (85.02% over three months), and a longer-term gain (12.11% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current AnaptysBio, Inc. (ANAB) stock price?

AnaptysBio, Inc. (NASDAQ: ANAB) stock price is $44.67 in the last trading session. During the trading session, ANAB stock reached the peak price of $46.27 while $42.50 was the lowest point it dropped to. The percentage change in ANAB stock occurred in the recent session was 1.99% while the dollar amount for the price change in ANAB stock was $0.87.

ANAB's industry and sector of operation?

The NASDAQ listed ANAB is part of Biotechnology industry that operates in the broader Healthcare sector. AnaptysBio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ANAB?

Ms. Beth Mueller
Senior Vice President of HR
Dr. Martin Dahl Ph.D.
Senior Vice President of Research
Mr. Eric J. Loumeau
Chief Legal Officer
Mr. Daniel R. Faga
Interim Pres & Chief Executive Officer and Director
Mr. Hamza Suria M.B.A., M.Sc.
Advisory
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.
Chief Medical Officer
Mr. Dennis M. Mulroy
Chief Financial Officer
Mr. Benjamin Stone
Senior Vice President of Corporation Devel.

How ANAB did perform over past 52-week?

ANAB's closing price is 265.85% higher than its 52-week low of $12.21 where as its distance from 52-week high of $52.47 is -14.87%.

How many employees does ANAB have?

Number of ANAB employees currently stands at 136.

Link for ANAB official website?

Official Website of ANAB is: https://www.anaptysbio.com

How do I contact ANAB?

ANAB could be contacted at phone 858 362 6295 and can also be accessed through its website. ANAB operates from 10770 Wateridge Circle, San Diego, CA 92121-5801, United States.

How many shares of ANAB are traded daily?

ANAB stock volume for the day was 591.81K shares. The average number of ANAB shares traded daily for last 3 months was 540.95K.

What is the market cap of ANAB currently?

The market value of ANAB currently stands at $1.24B with its latest stock price at $44.67 and 27.69M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	136
Beta	0.32
Sales or Revenue	$17.16M
5Y Sales Change%	2.145%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ANAB Company Profile and Key Details

AnaptysBio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Company Overview

Price Forecast & Outlook

Key Takeaways